Cronin Group Plc is a discovery company focussing on developing a number of projects targeting important new chemicals, materials, formulations, and pharmaceuticals in important commercial areas
We have a passion for the discovery, design, and digitization of solutions combining chemical, materials and pharmaceutical discovery, and aiming to reduce the cost and feasibility of the discovery and manufacturing process over a range of areas.
We are interested in hearing from research teams of companies with novel discovery ideas. If you are interested in finding out more about working with Cronin Group Plc please contact us at firstname.lastname@example.org
Prof. Lee Cronin
Founding Scientific Director
Professor Cronin is the Regius Chair of Chemistry in the Department Chemistry at the University. He was elected to the Fellowship of the Royal Society of Edinburgh, the Royal Society of Chemistry, and appointed to the Gardiner Chair in April 2009. He was awarded a Philip Leverhulme Prize by the Leverhulme Trust in 2007. He was awarded the Corday-Morgan medal of the Royal Society of Chemistry in 2012. Professor Cronin has a large active group at the University of Glasgow performing cutting-edge research into how complex chemical systems, created from non-biological building blocks, can have real-world applications with wide impact. Professor Cronin has published in excess of 300 peer-reviewed articles in a number of journals and has given over 280 invited presentations at conferences and universities worldwide.
Mark Warne became Executive Chairman of Cronin Group Plc in April 2017. He is also Head of IP Group’s Healthcare division, which at the end of December 2016, had shareholdings in 27 companies valued at over £330 million. Dr Warne represents IP Group on the boards of a number of its portfolio companies, both quoted and private. He has been at IP Group since 2008 and has extensive experience in building world changing healthcare businesses as well as in managing transactions including portfolio company IPOs, financings and M&A. Dr. Warne joined IP Group from pre clinical drug discovery contract research organisation, Exelgen, where he was Managing Director. He spent eight years at Exelgen (formerly known as Tripos Discovery Research) where he also held positions in licensing and strategic affairs, project management and research. Dr Warne has a PhD in Computational Chemistry, an MSc in Colloid Science and a BSc in Chemistry, all from the University of Bristol. Mark is a Chartered Chemist and member of the Royal Society of Chemistry.
Michael Bretherton is a chartered accountant having trained at PriceWaterhouse and acted as Finance Director in a number of public and private firms. His principal role from May 2006 to July 2014 was that of Finance Director of Channel Islands' based ORA Capital Partners Limited, an investment company with active interests in early stage growth companies. Mr. Bretherton is also Chairman of Sarossa plc which invests in technology companies.
James Ede-Golightly is chairman of East Balkan Properties Plc and Quoram Plc and has extensive experience as a non-executive on the boards of AIM-quoted companies with international business interests. James was a founder of ORA Capital Partners in 2006, having previously worked as an analyst at Merrill Lynch Investment Managers and Commerzbank. He is a CFA Charterholder and holds an MA in economics from Cambridge University. In 2012, he was awarded New Chartered Director of the Year by the Institute of Directors.
Laurence Ede was the Managing Director and co-owner of Tocris Bioscience, a company producing chemical compounds for pharmaceutical research, when it was sold to Techne Corporation for £75M in 2011. Mr. Ede had previously led the Management Buyout of Tocris for £14M five years earlier and grew its value by focusing on developing the business to be an increasingly significant provider of products within the life science arena. Mr. Ede is currently a non-executive director of Ubiquigent Ltd, a drug discovery services company using research tools and chemistry to pursue ubiquitin system-focused drug discovery programmes. He has a BSc in Chemistry from Reading University and an MBA from the University of Bath.
Advisory Committee Profiles
Riccardo Pigliucci brings his vast experience as a life science business leader to Cronin Group Plc. He is currently Managing Partner of Aldwych Associates, LLP, a management and technology consulting partnership. Mr. Pigliucci has held executive roles including CEO of both Discovery Partners International and Life Sciences International PLC, suppliers of products and services to life science industry, and President and COO of The Perkin-Elmer Corporation, a global life sciences company. In a non-executive capacity, Mr. Pigliucci currently serves as Chairman of Medaphor PLC, a provider of advanced ultrasound training simulators for medical professionals and in recent years he has also notably been a director for Dionex, Affymetrix and Biosphere Medical.
Paul Landau has a strong track record of taking innovative ideas off the drawing board and turning them into commercial reality. He was a pioneer in the wearable technology category, founding Fitbug Limited in 2005 after he identified a lack of technology being used in the wellness space. He foresaw that devices combined with digital technology and the internet could invoke changes in the behaviour of individuals with regard to their health. Mr Landau acted as CEO of Fitbug until November 2015. Prior to Fitbug he worked in the technology sector, starting at Accenture in 1998 specialising in systems implementations and process improvement projects for international blue-chip clients. Paul has a degree in Management Sciences (BSc.) from the University of Manchester.